DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/bjk5qr/pancreatic_ductal) has announced the addition of the "Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Pancreatic Ductal Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Ductal Adenocarcinoma and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Centrose Llc
- Clovis Oncology, Inc.
- F. Hoffmann-La Roche Ltd.
- FibroGen, Inc.
- Gilead Sciences, Inc.
- Incuron, LLC
- InvivoGen Therapeutics
- Medisyn Technologies, Inc.
- Merck & Co., Inc.
- Nerviano Medical Sciences S.r.l.
- OncoMed Pharmaceuticals, Inc.
- Pfizer Inc.
- SillaJen Co. Ltd.
- rucaparib phosphate
- Small Molecule to Inhibit Wnt Signal and eIF5A for Pancreatic Cancer
- Small Molecules to Modulate GLT-1 for Pancreatic Ductal Adenocarcinoma
For more information visit http://www.researchandmarkets.com/research/bjk5qr/pancreatic_ductal